William Blair research analyst Myles Minter was quoted in the Irish Independent after Alzheimer’s drug Leqembi became the first drug approved in the European Union to treat the disease.

“The decision to exclude those with two copies of the gene is the regulator leaning on the side of safety,” Minter wrote in his note that was cited by the publication.